blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development

Company profile
Ticker
BPMC
Exchange
Website
CEO
Jeffrey Albers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Blueprint Medicines Security Corporation • Blueprint Medicines (Switzerland) GmbH • Blueprint Medicines (Netherlands) B.V. • Blueprint Medicines (UK) Ltd. • Blueprint Medicines (Germany) GmbH • Blueprint Medicines Spain, S.L. • Blueprint Medicines (France) SAS • Blueprint Medicines (Italy) S.r.L. ...
BPMC stock data
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
26 Oct 23
8-K
Blueprint Medicines Reports Third Quarter 2023 Results
26 Oct 23
8-K
Other Events
25 Aug 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Blueprint Medicines Reports Second Quarter 2023 Results
2 Aug 23
8-K
Other Events
30 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
27 Jun 23
8-K
Entry into a Material Definitive Agreement
25 May 23
8-K
FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
22 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
Transcripts
BPMC
Earnings call transcript
2023 Q3
26 Oct 23
BPMC
Earnings call transcript
2023 Q2
2 Aug 23
BPMC
Earnings call transcript
2023 Q2
2 Aug 23
BPMC
Earnings call transcript
2023 Q1
4 May 23
BPMC
Earnings call transcript
2022 Q4
16 Feb 23
BPMC
Earnings call transcript
2022 Q2
2 Aug 22
BPMC
Earnings call transcript
2022 Q1
3 May 22
BPMC
Earnings call transcript
2021 Q4
16 Feb 22
BPMC
Earnings call transcript
2021 Q3
28 Oct 21
BPMC
Earnings call transcript
2021 Q2
29 Jul 21
Latest ownership filings
144
Notice of proposed sale of securities
7 Dec 23
4
Christopher K. Murray
6 Dec 23
144
Notice of proposed sale of securities
4 Dec 23
4
Jeffrey W. Albers
4 Dec 23
4
Jeffrey W. Albers
28 Nov 23
144
Notice of proposed sale of securities
24 Nov 23
SC 13G/A
FMR LLC
13 Nov 23
4
Jeffrey W. Albers
3 Nov 23
4
Christopher K. Murray
30 Oct 23
4
Fouad Namouni
5 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 65.67 mm | 65.67 mm | 65.67 mm | 65.67 mm | 65.67 mm | 65.67 mm |
Cash burn (monthly) | 5.40 mm | 19.25 mm | 44.51 mm | 46.06 mm | 34.83 mm | 39.94 mm |
Cash used (since last report) | 12.26 mm | 43.65 mm | 100.94 mm | 104.48 mm | 78.99 mm | 90.60 mm |
Cash remaining | 53.41 mm | 22.02 mm | -35.28 mm | -38.81 mm | -13.33 mm | -24.93 mm |
Runway (months of cash) | 9.9 | 1.1 | -0.8 | -0.8 | -0.4 | -0.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 215 |
Opened positions | 27 |
Closed positions | 33 |
Increased positions | 93 |
Reduced positions | 55 |
13F shares | Current |
---|---|
Total value | 3.20 tn |
Total shares | 64.92 mm |
Total puts | 445.41 k |
Total calls | 181.75 k |
Total put/call ratio | 2.5 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 6.59 mm | $330.84 bn |
FMR | 6.09 mm | $305.60 bn |
Vanguard | 5.97 mm | $299.67 bn |
T. Rowe Price | 5.50 mm | $275.85 bn |
Wellington Management | 5.08 mm | $255.14 bn |
Rock Springs Capital Management | 2.69 mm | $134.86 bn |
STT State Street | 2.63 mm | $131.86 bn |
T. Rowe Price Investment Management | 2.46 mm | $123.36 bn |
JPM JPMorgan Chase & Co. | 1.69 mm | $85.08 bn |
MCQEF Macquarie | 1.58 mm | $79.34 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Dec 23 | Christopher K. Murray | Common Stock | Sell | Dispose S | No | Yes | 71.43 | 600 | 42.86 k | 24,495 |
30 Nov 23 | Jeffrey W. Albers | Common Stock | Sell | Dispose S | No | Yes | 70.55 | 5,000 | 352.75 k | 176,050 |
30 Nov 23 | Jeffrey W. Albers | Common Stock | Option exercise | Acquire M | No | Yes | 36.05 | 5,000 | 180.25 k | 181,050 |
30 Nov 23 | Jeffrey W. Albers | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 36.05 | 5,000 | 180.25 k | 155,000 |
24 Nov 23 | Jeffrey W. Albers | Common Stock | Sell | Dispose S | No | Yes | 67.81 | 7,036 | 477.11 k | 176,050 |
24 Nov 23 | Jeffrey W. Albers | Common Stock | Sell | Dispose S | No | Yes | 67.25 | 7,964 | 535.58 k | 183,086 |
24 Nov 23 | Jeffrey W. Albers | Common Stock | Option exercise | Acquire M | No | Yes | 1.87 | 15,000 | 28.05 k | 191,050 |
24 Nov 23 | Jeffrey W. Albers | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 1.87 | 15,000 | 28.05 k | 30,073 |
3 Nov 23 | Jeffrey W. Albers | Common Stock | Sell | Dispose S | No | Yes | 60.13 | 1,485 | 89.29 k | 176,050 |
3 Nov 23 | Jeffrey W. Albers | Common Stock | Option exercise | Acquire M | No | Yes | 36.05 | 1,485 | 53.53 k | 177,535 |
News
Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To Know
27 Oct 23
Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To Know
27 Oct 23
Oppenheimer Upgrades Blueprint Medicines to Outperform, Announces $85 Price Target
27 Oct 23
Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $63
27 Oct 23
Barclays Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $58
27 Oct 23